SRL is commercially available for oral administration as an immunosuppressant given in a daily dosage of 2–10 mg (bioavailability 15 %, e.g., oral Rapamune, Pfizer) and as albumin-bound intravenous formulation (Fyarro) in a dose of 100  mg/m2 for cancer therapy. Here, ALB is linked to cancer.